Gabather AB (publ) (GABA.ST)
SEK 0.04
(-6.88%)
SEK 0.04
(-6.88%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 37 Thousand SEK | 100.43% |
| 2022 | -8.54 Million SEK | 49.69% |
| 2021 | -16.9 Million SEK | -15.9% |
| 2020 | -14.66 Million SEK | -3.31% |
| 2019 | -14.19 Million SEK | 29.77% |
| 2018 | -20.2 Million SEK | -104.67% |
| 2017 | -9.87 Million SEK | -26.0% |
| 2016 | -7.83 Million SEK | -31.87% |
| 2015 | -5.94 Million SEK | -130.75% |
| 2014 | -2.57 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -3.18 Million SEK | 0.0% |
| 2024 Q2 | -1.72 Million SEK | 0.0% |
| 2023 Q3 | -2.82 Million SEK | -73.18% |
| 2023 Q2 | -1.63 Million SEK | 19.64% |
| 2023 Q1 | -2.03 Million SEK | 17.36% |
| 2023 Q4 | -2.97 Million SEK | -5.02% |
| 2023 FY | - SEK | -10.88% |
| 2022 Q4 | -2.45 Million SEK | -18.33% |
| 2022 Q1 | -1.95 Million SEK | 65.41% |
| 2022 Q2 | -2.05 Million SEK | -5.54% |
| 2022 Q3 | -2.07 Million SEK | -0.97% |
| 2022 FY | - SEK | 49.69% |
| 2021 Q4 | -5.63 Million SEK | -49.96% |
| 2021 FY | - SEK | -15.9% |
| 2021 Q1 | -3.43 Million SEK | -3.4% |
| 2021 Q2 | -4.16 Million SEK | -21.14% |
| 2021 Q3 | -3.75 Million SEK | 9.66% |
| 2020 Q4 | -3.32 Million SEK | 24.74% |
| 2020 FY | - SEK | -3.31% |
| 2020 Q3 | -4.41 Million SEK | -68.15% |
| 2020 Q1 | -4.29 Million SEK | -18.14% |
| 2020 Q2 | -2.62 Million SEK | 38.94% |
| 2019 Q2 | -4.14 Million SEK | -12.15% |
| 2019 Q4 | -3.63 Million SEK | -34.08% |
| 2019 Q3 | -2.71 Million SEK | 34.49% |
| 2019 FY | - SEK | 29.77% |
| 2019 Q1 | -3.69 Million SEK | 9.21% |
| 2018 Q3 | -5.13 Million SEK | 15.73% |
| 2018 Q4 | -4.06 Million SEK | 20.82% |
| 2018 FY | - SEK | -104.67% |
| 2018 Q1 | -4.69 Million SEK | -45.48% |
| 2018 Q2 | -6.09 Million SEK | -29.94% |
| 2017 Q4 | -3.22 Million SEK | -83.08% |
| 2017 Q2 | -2.56 Million SEK | -10.66% |
| 2017 Q1 | -2.31 Million SEK | -4.28% |
| 2017 FY | - SEK | -26.0% |
| 2017 Q3 | -1.76 Million SEK | 31.31% |
| 2016 Q1 | -1.61 Million SEK | -15.73% |
| 2016 FY | - SEK | -31.87% |
| 2016 Q2 | -2.22 Million SEK | -37.71% |
| 2016 Q4 | -2.22 Million SEK | -25.37% |
| 2016 Q3 | -1.77 Million SEK | 20.28% |
| 2015 Q2 | -2.05 Million SEK | -70.82% |
| 2015 Q3 | -1.27 Million SEK | 37.96% |
| 2015 Q4 | -1.39 Million SEK | -9.45% |
| 2015 FY | - SEK | -130.75% |
| 2015 Q1 | -1.2 Million SEK | -30.05% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q4 | -925 Thousand SEK | -18.14% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q3 | -783 Thousand SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | 100.27% |
| AlzeCure Pharma AB (publ) | -37.86 Million SEK | 100.098% |
| BioGaia AB (publ) | 466.19 Million SEK | 99.992% |
| Enzymatica AB (publ) | -41.12 Million SEK | 100.09% |
| Enorama Pharma AB (publ) | -43.05 Million SEK | 100.086% |
| Klaria Pharma Holding AB (publ.) | -14.77 Million SEK | 100.251% |
| Moberg Pharma AB (publ) | -26.95 Million SEK | 100.137% |
| Nanexa AB (publ) | -70.79 Million SEK | 100.052% |
| Newbury Pharmaceuticals AB (publ) | -12.34 Million SEK | 100.3% |
| ODI Pharma AB | 1.36 Million SEK | 97.294% |
| Orexo AB (publ) | -22 Million SEK | 100.168% |
| Probi AB (publ) | 115.61 Million SEK | 99.968% |
| Swedencare AB (publ) | 484 Million SEK | 99.992% |
| Swedish Orphan Biovitrum AB (publ) | 7.23 Billion SEK | 99.999% |
| Toleranzia AB | -7.39 Million SEK | 100.5% |
| Vivesto AB | -89.75 Million SEK | 100.041% |